Parkinson's disease affects approximately 1 million U.S. adults and is the second most common neurodegenerative disease after Alzheimer's, with prevalence rising from 1-2% in adults aged 65 and older to 4-5% in those aged 85 and older. With 90,000 new diagnoses annually and a total U.S. economic burden of approximately $51.9 billion, Medicare beneficiaries with PD incur annual costs 2-3 times higher than non-PD controls. A 2024 ICD-10 update now requires documentation of both dyskinesia status and motor fluctuation status for accurate G20 coding, making clinical specificity a documentation-critical requirement with direct HCC and risk adjustment consequences.
AAVBC's Parkinson's Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering G20.x coding specificity, HCC/RAF mapping across PD and PD-related dementia categories, Hoehn and Yahr staging, MDS diagnostic criteria, MEAT documentation standards, first-line and escalation therapy guidance, contraindicated treatments, comorbidity screening, and case examples. Grounded in current AAN and MDS guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams document Parkinson's disease with the clinical precision that accurate risk adjustment and durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of this neurodegenerative disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Parkinson's disease affects approximately 1 million U.S. adults and is the second most common neurodegenerative disease after Alzheimer's, with prevalence rising from 1-2% in adults aged 65 and older to 4-5% in those aged 85 and older. With 90,000 new diagnoses annually and a total U.S. economic burden of approximately $51.9 billion, Medicare beneficiaries with PD incur annual costs 2-3 times higher than non-PD controls. A 2024 ICD-10 update now requires documentation of both dyskinesia status and motor fluctuation status for accurate G20 coding, making clinical specificity a documentation-critical requirement with direct HCC and risk adjustment consequences.
AAVBC's Parkinson's Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering G20.x coding specificity, HCC/RAF mapping across PD and PD-related dementia categories, Hoehn and Yahr staging, MDS diagnostic criteria, MEAT documentation standards, first-line and escalation therapy guidance, contraindicated treatments, comorbidity screening, and case examples. Grounded in current AAN and MDS guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams document Parkinson's disease with the clinical precision that accurate risk adjustment and durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of this neurodegenerative disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
